Please assess the completion status of the following clinical trial:

Trial Title: The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who has received prime vaccination of adenovirus type-5 vectored COVID-19 vaccine~* Able to understand the content of informed consent and willing to sign the informed consent~* Negative in HIV diagnostic test.~* Axillary temperature ≤37.0°C.~* General good health as established by medical history and physical examination.~* Able to complete 12 months visit~Exclusion Criteria:~* Family history of seizure, epilepsy, brain or mental disease~* Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.~* Woman who is pregnant, breast-feeding on day of enrollment, or become pregnant during the next 12 months~* Any acute fever disease or infections.~* History of SARS~* Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.~* Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last one year~* No spleen or functional spleen.~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Adenovirus Type-5 Vectored COVID-19 Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).